CLRB Cellectar Biosciences, Inc.

1.59
-0.08  -5%
Previous Close 1.67
Open 1.68
Price To book 1.63
Market Cap 21.40M
Shares 13,462,000
Volume 85,075
Short Ratio 13.30
Av. Daily Volume 156,786

SEC filingsSee all SEC filings

  1. 8-K - Current report 17894286
  2. S-3 - Registration statement under Securities Act of 1933 17892094
  3. 8-K - Current report 17884757
  4. 8-K - Current report 17877366
  5. 8-K - Current report 17854924

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced March 30, 2017. Initial data due 2H 2017.
CLR 131
Various lymphoma

Latest News

  1. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  2. Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference
  3. Cellectar Biosciences to Present at the LD Micro Invitational Conference
  4. Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings
  5. Edited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT
  6. Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance
  7. Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
  8. Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
  9. Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers
  10. UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
  11. Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells
  12. Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer
  13. Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors
  14. After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
  15. Edited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT
  16. Cellectar Biosciences Secures Japanese Patent

SEC Filings

  1. 8-K - Current report 17894286
  2. S-3 - Registration statement under Securities Act of 1933 17892094
  3. 8-K - Current report 17884757
  4. 8-K - Current report 17877366
  5. 8-K - Current report 17854924
  6. 8-K - Current report 17835542
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17832566
  8. 8-K - Current report 17804923
  9. 8-K - Current report 17788960
  10. DEF 14A - Other definitive proxy statements 17781112